Since 2011. An occasional commonplacing of the U.S. Circuit Courts of Appeal.
Neither an authoritative statement of the law nor legal advice. Quick work.
Given the differences in their designs, triangular atria alone are insufficient to establish the identity of total concept and feel necessary for copyright infringement; no reasonable minds could differ on whether there was a substantial similarity of expression in the designs.
Although the court erred in saying that attorneys fees awards were the rule rather than the excpetion, it did not abuse its discretion in the actual award of fees in this case.
Claim is ineligible for patent, because it recites abstract mathematical concepts without practical technological improvements beyond increasing statistical accuracy, and, taken as a whole, is embodied as well-known, routine and conventional actions of performing an algorithm on a computer.
(Perhaps. We don't know many things, but we especially don't know Patents.)
Claims are patent ineligible mathematical algorithms, basic processes fully disclosed in prior art, and with no real mechanical or computing architecture correlative.
Court erred in assigning the term the meaning it served in the description of the function of the device within an unclaimed surrounding mechanism.
The doctrine of equivalents is not a binary question of vitiation, but a reasoned inquiry that looks to the degree that the second device performs the same function, in the same way, and achieves the same result.
Again, perhaps. Not really at all Patent-savvy in this quarter.
Judicial review of a decision on estoppel during the institution and pendency of an IPR is appropriate, because the estoppel statute applies to the duration of the action, not just the decision to institute proceedings.
Board correctly did not estop the party's claim, since there was no evidence of actual control and direction between the interested party and the litigating party, and the pre-existing relationship was not one that suggested coordinated action.
Given the plain language of the statute, the claim that the interested party was not estopped from raising was fair, as that specific claim had not arisen in the earlier action.
Substantial evidence for Board's obviousness and disclosure determinations.
(Perhaps. We don't know many things, but we especially don't know Patents. As always, entertainment value only.)
Anticompetitive effects of a supplier's monopoly behaviour on downstream adjacent markets are beyond the reach of Sherman Act rule of reason analysis, as the relevant market is different.
Refusal to deal horizontally with another supplier is outside of S2 where there is no indication that the dealing was profitable for the deft, there was a valid business reason to end the dealing, and the refusal to deal wasn't targeted.
Absent intentional deception, breach of contract to deal horizontally with other suppliers doesn't create a monopoly harm unless a harm to competition - as opposed to competitors - is proved.
Patent royalty rates different than the current market value of the technology are not inherently anticompetitive under antitrust law.
As the products of the supplier's rivals inherently embody some of the packaged patents, the supplier's licensing of the downstream use of its terchnology within its rivals products is not an inherently anticompetitive surcharge on its rivals products. Subsequent low but non-predatory pricing of its own units is also not an inherently anticompetitive behaviour.
A supplier's requirement that a downstream manufacturer commit to a license for products both supplied by the supplier and its rivals does not distort the area of effective competition; any unfair pricing of the license sounds in patent law, not antitrust.
Even if the exclusive dealing contracts that the supplier claimed were merely volume contracts in fact substantially foreclosed competition in the relevant markets, past harms do not justify a prospective injunction. And there were no viable competitors at the time.